elotuzumab (Empliciti)
Jump to navigation
Jump to search
Indications
- relapsed or refractory multiple myeloma
- used in combination with lenalidomide & dexamethasone[1]
Dosage
400 MG Injection [Empliciti]
Adverse effects
- lymphocytopenia
- neutropenia
- fatigue,
- pneumonia
- infusion reactions
Mechanism of action
- immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7)[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Lonial S, Dimopoulos M, Palumbo A et al Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31.. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26035255